This combination also provides a practical strategy for reducing residual cardiometabolic risk
Retatrutide activates three distinct G-protein coupled receptors, triggering cAMP-mediated signaling that enhances postprandial insulin secretion, improves glucose-dependent nutrient sensing, and increases hepatic fatty acid oxidation
Switching from semaglutide to retatrutide may be appropriate in some situations, but it should only be done under medical supervision
Tirzepatide, an FDA-approved dual GIP/GLP-1 receptor agonist for type 2 diabetes and obesity, works through incretin-based glucose regulation and appetite suppression
Also, L-carnitine hepatoprotection and nephroprotection may provide a possible clue for chemobrain prevention in cancer patients on Doxorubicin and Cyclophosphamide treatment
This decision must be made by a licensed provider based on your specific medical history